{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Musculoskeletal+and+Connective+Tissue+Diseases",
    "query": {
      "condition": "Musculoskeletal and Connective Tissue Diseases"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1877,
    "total_pages": 188,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Musculoskeletal+and+Connective+Tissue+Diseases&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T10:57:34.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03420963",
      "title": "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Cutaneous Melanoma",
        "Recurrent Lip and Oral Cavity Carcinoma",
        "Recurrent Malignant Endocrine Neoplasm",
        "Recurrent Malignant Female Reproductive System Neoplasm",
        "Recurrent Malignant Male Reproductive System Neoplasm",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Malignant Neoplasm of Multiple Primary Sites",
        "Recurrent Malignant Oral Neoplasm",
        "Recurrent Malignant Pharyngeal Neoplasm",
        "Recurrent Malignant Skin Neoplasm",
        "Recurrent Malignant Soft Tissue Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Malignant Thyroid Gland Neoplasm",
        "Recurrent Malignant Urinary System Neoplasm",
        "Refractory Cutaneous Melanoma",
        "Refractory Malignant Bone Neoplasm",
        "Refractory Malignant Endocrine Neoplasm",
        "Refractory Malignant Female Reproductive System Neoplasm",
        "Refractory Malignant Male Reproductive System Neoplasm",
        "Refractory Malignant Mesothelioma",
        "Refractory Malignant Neoplasm of Multiple Primary Sites",
        "Refractory Malignant Oral Neoplasm",
        "Refractory Malignant Pharyngeal Neoplasm",
        "Refractory Malignant Skin Neoplasm",
        "Refractory Malignant Soft Tissue Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Malignant Thyroid Gland Neoplasm",
        "Refractory Malignant Urinary System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Months to 40 Years"
      },
      "enrollment_count": 12,
      "start_date": "2018-08-31",
      "completion_date": "2026-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03420963"
    },
    {
      "nct_id": "NCT07295847",
      "title": "A Study of AZD0120 in Autoimmune Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Idiopathic Inflammatory Myopathies",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "AZD0120",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2026-01-09",
      "completion_date": "2028-02-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07295847"
    },
    {
      "nct_id": "NCT02638948",
      "title": "Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "BMS-986142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 508,
      "start_date": "2016-02-16",
      "completion_date": "2018-05-03",
      "has_results": true,
      "last_update_posted_date": "2019-05-28",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • Fullerton, California • Hemet, California + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02638948"
    },
    {
      "nct_id": "NCT00589485",
      "title": "Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteoarthritis",
        "Rheumatoid Arthritis",
        "Traumatic Arthritis",
        "Knee Arthritis"
      ],
      "interventions": [
        {
          "name": "Simplex® Bone Cement",
          "type": "DEVICE"
        },
        {
          "name": "Cobalt™ Bone Cement",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Zimmer Biomet",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2006-11",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 1,
      "location_summary": "Warsaw, Indiana",
      "locations": [
        {
          "city": "Warsaw",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589485"
    },
    {
      "nct_id": "NCT00042406",
      "title": "Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Humax-CD4",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2002-03-04",
      "completion_date": "2003-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-28",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 50,
      "location_summary": "Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042406"
    },
    {
      "nct_id": "NCT00055133",
      "title": "A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Micellar Paclitaxel for Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angiotech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2002-09",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2008-07-29",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Daytona Beach, Florida + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055133"
    },
    {
      "nct_id": "NCT05417789",
      "title": "Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "TGCT"
      ],
      "interventions": [
        {
          "name": "Emactuzumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SynOx Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2024-10-09",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 10,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Overland Park, Kansas + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05417789"
    },
    {
      "nct_id": "NCT00233558",
      "title": "Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "adalimumab (up to 9 months exposure)",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2005-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-04-24",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 1,
      "location_summary": "North Chicago, Illinois",
      "locations": [
        {
          "city": "North Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00233558"
    },
    {
      "nct_id": "NCT06991114",
      "title": "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Rheumatoid Arthritis (RA)",
        "Idiopathic Inflammatory Myopathies (IIMs)",
        "Systemic Sclerosis (SSc)",
        "Rheumatoid Arthritis (RA",
        "IIM",
        "Myositis",
        "Scleroderma",
        "Sjogren Syndrome",
        "Sjogrens Disease"
      ],
      "interventions": [
        {
          "name": "Allogeneic NK Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-07-09",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 31,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06991114"
    },
    {
      "nct_id": "NCT02784106",
      "title": "Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "M2951",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2016-07-31",
      "completion_date": "2017-11-14",
      "has_results": true,
      "last_update_posted_date": "2018-07-17",
      "last_synced_at": "2026-07-22T10:57:34.606Z",
      "location_count": 1,
      "location_summary": "Billerica, Massachusetts",
      "locations": [
        {
          "city": "Billerica",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784106"
    }
  ]
}